Pfizer’s Chief Scientific Officer Mikael Dolsten expects pandemic levels of COVID-19 cases in some locations for the next year or two.
If you are looking for the news that the pandemic is almost over don't talk to Pfizer's Chief Scientific Officer Mikael Dolsten. He recently told company investors his thoughts on when it will be over, “When and how exactly this happens will depend on evolution of the disease, how effectively society deploys vaccines and treatments, and equitable distribution to places where vaccination rates are low, the emergence of new variants could also impact how the pandemic continues to play out.”
Pfizer anticipates its COVID-19 vaccine, developed with BioNTech SE (22UAy.DE), to produce $31 billion in revenue next year. 4 billion shots expected next year.In a clinical trial, Paxlovid, an investigational antiviral tablet, reduced hospitalizations and deaths in high-risk individuals by over 90%. According to Refinitiv’s IBES data, three analysts expect sales of $15-$25 billion next year.
Pfizer’s projection came after the Omicron variety emerged last month, which contains over 50 changes compared to the original virus. This has limited the efficiency of two doses of the vaccine and raised concerns about global spread. Before the Omicron variant, renowned American disease specialist Anthony Fauci predicted the epidemic would end in 2022.